Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment

Aggressive lymphomas are curable with doxorubicin-based chemotherapy. In patients presenting with elevated serum bilirubin, doxorubicin is commonly dose reduced or delayed based on limited pharmacokinetic data. We evaluated plasma pharmacokinetics of doxorubicin and its metabolite doxorubicinol as w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Catherine, Cole, Diane E., Steinberg, Seth M., Lucas, Nicole, Dombi, Eva, Melani, Christopher, Roschewski, Mark, Balis, Frank, Widemann, Brigitte C., Wilson, Wyndham H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979767/
https://www.ncbi.nlm.nih.gov/pubmed/35882475
http://dx.doi.org/10.1182/bloodadvances.2022007431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979767/
https://www.ncbi.nlm.nih.gov/pubmed/35882475
http://dx.doi.org/10.1182/bloodadvances.2022007431

Ejemplares similares